Canada markets closed

Microbix Biosystems Inc. (MBX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.52000.0000 (0.00%)
At close: 03:53PM EDT
Full screen
Previous Close0.5200
Open0.5000
Bid0.5000 x 0
Ask0.5200 x 0
Day's Range0.5000 - 0.5200
52 Week Range0.4200 - 0.8700
Volume9,500
Avg. Volume33,817
Market Cap71.196M
Beta (5Y Monthly)N/A
PE Ratio (TTM)17.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSept 02, 1999
1y Target EstN/A
  • GlobeNewswire

    Microbix Reports Results for Q3 Fiscal 2022

    Q3 Sales of $5.0 million, Q3 Net Earnings of $0.6 millionMISSISSAUGA, Ontario, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022 (“Q3” and “YTD”), with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to the

  • GlobeNewswire

    Microbix Executes Substantial QAPs Supply Agreement

    Microbix QAPs to Support Molecular & Antigen Test Platforms for Multiple DiseasesMISSISSAUGA, Ontario, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the execution of a purchase and supply agreement (“Agreement”) by which Microbix “QAPs™” quality assessment products will support assays on industry-leading molecular (PCR) and antigen-based point-of-care testing platforms. QAPs mimic p

  • GlobeNewswire

    Microbix Presenting STI Multiplex Test Controls at AACC

    Quality Control Materials for Genital Ulcer Disease Molecular AssaysMISSISSAUGA, Ontario, July 26, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it is presenting about the utility of its multi-pathogen (“multiplex”) and swab-formatted Quality Assessment Products (“QAPs™”) to monitor molecular assays that detect and distinguish between four sexually-transmitted infections (each an “STI”) that